Study of adebrelimab plus chemo before and after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have stomach cancer or cancer where the stomach meets the esophagus that can be removed with surgery.
- You have not received any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You have no active hepatitis B or other serious infections.
- You agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two drugs (mecapegfilgrastim and adebrelimab) to standard chemotherapy before surgery can help treat advanced stomach or gastroesophageal junction cancer that has not yet spread. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (capecitabine and oxaliplatin) for people with stomach cancer or cancer where the stomach meets the esophagus. It aims to see if this combination is safe and effective for patients who have not had prior treatment for advanced disease.
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.